Tokyo-based medical AI developer Aillis, Inc., led by CEO Sho Okiyama, has received the Review Committee Special Award at the Japan Startup Awards 2026. The award ceremony was held at the Prime Minister's Office on September 25. The recognition highlights the company's efforts to address healthcare challenges and advance the real-world implementation of artificial intelligence in medicine.
Ceremony at the Prime Minister's Office
The formal ceremony took place in Tokyo on September 25, bringing together government representatives and members of Japan's startup ecosystem. Aillis was recognized for its vision of addressing challenges in healthcare and its advanced efforts to bring medical AI beyond research and into practical use. The award underscores the company's progress in translating emerging technologies into tools designed for real clinical environments.
A National Platform for Startup Recognition
The Japan Startup Awards is a national initiative recognizing entrepreneurs and startups that create socially impactful businesses and can serve as role models for the next generation. The program is organized by seven Japanese ministries covering the economy, agriculture, education, health and labor, land and infrastructure, internal affairs, and defense. An expert review committee selects recipients after assessing their business vision, innovation, entrepreneurial ambition, and potential for expansion.
Evaluation Criteria and Selection Process
Candidates are evaluated on the clarity of their business vision and the novelty and innovative nature of their activities. The review committee also examines the level of entrepreneurial challenge involved and whether the business has the potential to scale. These criteria are intended to identify startups capable of creating meaningful social impact while developing sustainable and expandable businesses.
Aillis and the Social Implementation of Medical AI
Aillis has focused on addressing challenges in clinical settings while moving beyond research and development toward the practical deployment of medical AI. The company has worked with a diverse group of stakeholders to build the alignment needed to introduce artificial intelligence technologies into healthcare environments. Its approach reflects an emphasis on overcoming the technical, clinical, and institutional barriers involved in bringing advanced medical technology into everyday practice.
Vision for a Continuously Improving Healthcare System
Following the award, Aillis said it will continue promoting the social implementation of advanced technologies, including artificial intelligence. The company aims to create a system in which medical data and knowledge circulate continuously, allowing healthcare itself to improve and evolve over time. Its broader goal is to help ensure that people can receive appropriate diagnosis and treatment regardless of where they live while supporting healthcare that patients can understand and trust.
About Aillis, Inc.
Founded in 2017, Aillis operates under a mission centered on creating open healthcare that people can build together. The company is led by practicing physician Sho Okiyama and brings together healthcare professionals, former government officials, data scientists specializing in medical AI, and professionals with experience at major medical device manufacturers. Its team develops AI-powered medical devices that use machine learning to digitize and apply physicians' knowledge and clinical techniques.
Company Operations and Headquarters
Headquartered in Chiyoda Ward, Tokyo, Aillis develops, manufactures, and sells AI-powered medical devices. The company also conducts research and development involving machine learning technologies and artificial intelligence models for medical applications. Its combination of clinical, regulatory, scientific, and medical-device expertise supports its efforts to bring AI technologies into practical healthcare settings.
The Japan Startup Awards 2026 recognition highlights Aillis's work to advance the practical use of medical AI in Japan. By combining clinical expertise, regulatory knowledge, and artificial intelligence development, the company is working to make advanced technology a more integrated part of healthcare delivery. Aillis plans to continue developing systems that allow medical knowledge and data to circulate more effectively and contribute to better access to appropriate care.